Under the direction of Michael Peters, PhD, VCU researchers will develop and optimize peptide biomimetics to achieve high binding rates to the receptor-binding domain of the SARS-CoV-2 spike protein at the nanomolar level, with demonstrated negligible toxicity, according to Hoth. They will conduct point mutations in silico in an effort to improve the stability and binding properties of these decoy peptides, the company said.

Next, these optimized, in silico peptides will be synthesized and experimentally characterized through structure determination, binding to the spike protein, and cell challenge assays with SARS-CoV-2, according to the firm. Hoth has secured exclusive license to this peptide COVID-19 therapeutic.

SARS-CoV-2 rewires host proteins to promote infection
To successfully infect human cells, SARS-CoV-2 may hijack host proteins in target cells to promote its own replication. Researchers may be able to leverage...

ImmunoPrecise identifies SARS-CoV-2 neutralizing antibodies
ImmunoPrecise Antibodies has identified several lead candidate antibodies with high neutralizing activity in vitro that are being manufactured for further...

NIH researchers investigate virulence of SARS-CoV-2 virus
What makes the SARS-CoV-2 virus so virulent? Researchers from the U.S. National Institutes of Health (NIH) analyzed the genomics of the virus -- and compared...

FDA researchers explore vaccine responses to SARS-CoV-2 antigens
Different proteins associated with SARS-CoV-2, the virus that causes COVID-19, generate unique immune responses when given to rabbits as immunizations,...

SARS-CoV mAb shown to block SARS-CoV-2
Antibodies from recovered SARS-CoV patients appear to block SARS-CoV-2 infectivity and could help in the development of antiviral treatments or vaccines,...